[go: up one dir, main page]

DK0924201T3 - Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer - Google Patents

Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer

Info

Publication number
DK0924201T3
DK0924201T3 DK99101677T DK99101677T DK0924201T3 DK 0924201 T3 DK0924201 T3 DK 0924201T3 DK 99101677 T DK99101677 T DK 99101677T DK 99101677 T DK99101677 T DK 99101677T DK 0924201 T3 DK0924201 T3 DK 0924201T3
Authority
DK
Denmark
Prior art keywords
cyclooxygenase
inhibitors
tricyclic substituted
pyrazolylbenzenesulfonamides
substituted pyrazolylbenzenesulfonamides
Prior art date
Application number
DK99101677T
Other languages
Danish (da)
English (en)
Inventor
Roland S Rogers
John J Talley
Thomas D Penning
Paul W Collins
Donald J Rogier Jr
James W Malecha
Julie M Miyashiro
Stephen R Bertenshaw
Matthew J Granets
Kathy L Rogers
Jeffrey S Carter
Stephen H Docter
Stella S Yu
Ish K Khanna
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26857022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0924201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/160,594 external-priority patent/US5466823A/en
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0924201T3 publication Critical patent/DK0924201T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK99101677T 1993-11-30 1994-11-14 Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer DK0924201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,594 US5466823A (en) 1993-11-30 1993-11-30 Substituted pyrazolyl benzenesulfonamides
US08/223,629 US5521207A (en) 1993-11-30 1994-04-06 Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation

Publications (1)

Publication Number Publication Date
DK0924201T3 true DK0924201T3 (da) 2002-05-21

Family

ID=26857022

Family Applications (3)

Application Number Title Priority Date Filing Date
DK99101697T DK0923933T3 (da) 1993-11-30 1994-11-14 Substituerede pyrazolyl-benzensulfonamider til anvendelse ved behandling af inflammation
DK95902444T DK0731795T3 (da) 1993-11-30 1994-11-14 Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
DK99101677T DK0924201T3 (da) 1993-11-30 1994-11-14 Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK99101697T DK0923933T3 (da) 1993-11-30 1994-11-14 Substituerede pyrazolyl-benzensulfonamider til anvendelse ved behandling af inflammation
DK95902444T DK0731795T3 (da) 1993-11-30 1994-11-14 Substituerede pyrazolylbenzensulfonamider til behandling af inflammation

Country Status (26)

Country Link
US (2) US5760068A (de)
EP (1) EP0731795B1 (de)
JP (3) JP3025017B2 (de)
KR (3) KR100263817B1 (de)
CN (4) CN1268614C (de)
AT (4) ATE187965T1 (de)
CA (4) CA2177576C (de)
CY (2) CY2237B1 (de)
CZ (1) CZ294630B6 (de)
DE (6) DE69429836T2 (de)
DK (3) DK0923933T3 (de)
ES (4) ES2141916T3 (de)
FI (1) FI115053B (de)
FR (1) FR09C0007I2 (de)
GR (1) GR3032696T3 (de)
HK (2) HK1013649A1 (de)
HU (1) HU223824B1 (de)
LU (2) LU90698I2 (de)
NL (1) NL300024I2 (de)
NO (1) NO306460B1 (de)
NZ (3) NZ276885A (de)
PL (1) PL180717B1 (de)
PT (3) PT731795E (de)
RO (1) RO118291B1 (de)
RU (1) RU2139281C1 (de)
WO (1) WO1995015316A1 (de)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716991B1 (en) * 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
WO1996037476A1 (en) * 1995-05-25 1996-11-28 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
EP0828718A1 (de) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo-substituierte hydroxaminsäurederivate als cyclooxygenase-2 und 5-lipoxygenase inhibitoren
AU6111796A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
NZ322674A (en) * 1995-10-17 1999-08-30 Searle & Co Method of detecting cyclooxygenase-2
EP0880363B1 (de) 1996-02-13 2002-09-11 G.D. SEARLE & CO. Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
ES2169351T3 (es) 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
EP0880362B1 (de) 1996-02-13 2005-05-25 G.D. SEARLE & CO. Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
EP1288206B1 (de) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
WO1998016227A1 (en) 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
IT1287174B1 (it) * 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
NZ335853A (en) * 1996-11-19 2002-02-01 G Method of using COX-2 inhibitors as anti-angiogenic agents
CA2285434A1 (en) * 1997-04-03 1998-10-08 Philip Needleman Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
EP1498140A2 (de) * 1997-04-18 2005-01-19 G.D. Searle & Co. Verfahren zur Verwendung von Cyclooxygenase-2 Hemmern zur Vorbeugung von kardiovakulären Erkrankungen
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
AUPO941497A0 (en) * 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU750356B2 (en) * 1997-09-24 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. 1,5-diphenylpyrazole derivatives
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
EP1068187A1 (de) * 1998-04-08 2001-01-17 Abbott Laboratories Pyrazole als inhibitoren der cytokinproduktion
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
AU4308300A (en) * 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
US6573290B1 (en) * 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
PT1104758E (pt) 1999-12-03 2003-12-31 Pfizer Prod Inc Derivados de acetileno como agentes anti-inflamatorios/analgesicos
DE60018792T2 (de) 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
ATE252576T1 (de) 1999-12-03 2003-11-15 Pfizer Prod Inc Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
OA11831A (en) * 1999-12-08 2005-08-23 Pharmacia Corp Polymorphic crystalline forms of celecoxib.
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
BR0008058A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
CN100486573C (zh) 1999-12-23 2009-05-13 硝化医药股份有限公司 硝基化的和亚硝基化的环加氧酶-2抑制剂、组合物及其用途
WO2001074823A2 (en) * 2000-03-31 2001-10-11 Takeda Chemical Industries, Ltd. Fused heterocyclic derivatives, their production and use
AU2001253749A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
US6403629B2 (en) * 2000-05-02 2002-06-11 J.B. Chemical And Pharmaceuticals Limited Heterocyclic compounds for therapeutic use
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
CA2411960C (en) * 2000-06-13 2010-10-12 Wyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
TR200001872A2 (tr) 2000-06-26 2002-01-21 Fako �La�Lari A.� 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem.
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PL359556A1 (en) 2000-07-20 2004-08-23 Lauras As Method - use of cox-2 inhibitors for preventing immunodeficiency
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US20020136784A1 (en) * 2000-12-15 2002-09-26 Pharmacia Corporation Selective COX-2 inhibition from plant extracts
JP2004517838A (ja) * 2000-12-15 2004-06-17 ファルマシア・コーポレーション 非食用植物抽出物による選択的ｃｏｘ−２阻害
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002062391A2 (en) * 2001-02-02 2002-08-15 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
EP1273582B1 (de) 2001-07-05 2005-06-29 Pfizer Products Inc. Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0119477D0 (en) * 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US6956052B2 (en) * 2001-09-19 2005-10-18 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
AR036608A1 (es) * 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
US20040126438A1 (en) * 2001-12-13 2004-07-01 Obukowicz Mark G. Selective cox-2 inhibition from plant extracts
US20040062823A1 (en) * 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
TW562937B (en) * 2002-03-26 2003-11-21 Nanya Technology Corp Method for fast determining defect type of word line
JP2005528384A (ja) * 2002-04-08 2005-09-22 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 増殖性細胞においてアポトーシスを誘導するための化合物および方法
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
US20040006100A1 (en) * 2002-04-18 2004-01-08 Stephenson Diane T. Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S)
WO2003095430A1 (en) * 2002-05-09 2003-11-20 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
ZA200409434B (en) * 2002-05-24 2006-10-25 Pharmacia Corp Synthesis of diary pyrazoles
US7087630B2 (en) 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) * 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
EP1546128B1 (de) * 2002-08-19 2006-05-03 Glaxo Group Limited Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
SI1572173T1 (sl) 2002-12-13 2010-08-31 Warner Lambert Co Alfa-2-delta ligand za zdravljenje simptomov spodnjega dela sečil
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
EP2339328A3 (de) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040220249A1 (en) * 2003-01-29 2004-11-04 Children's Medical Center Corporation Prevention of surgical adhesions using selective COX-2 inhibitors
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060142368A1 (en) * 2003-04-08 2006-06-29 Ching-Shih Chen Compounds and methods for inducing apoptosis in proliferating cells
EP1745791B1 (de) * 2003-05-07 2013-06-26 Osteologix A/S Behandlung von Knorpel/Knochen-Erkrankungen mit wasserlöslichen Strontiumsalzen
EP2266584B1 (de) * 2003-05-07 2012-09-05 Osteologix A/S Strontium-Vitamin D-Zusammensetzung zur Prophylaxe/Behandlung von Knorpel- und Knochenzuständen
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4－芳基－5h－噻吩－2－酮衍生物、其制法和用途
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
DK1696907T3 (da) * 2003-10-03 2013-06-24 Univ Ohio State Res Found PDK-1/AKT Signalinhibitorer
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
US20060014813A1 (en) * 2003-11-26 2006-01-19 Patrick Connelly Pharmaceutical compounds that regenerate in vivo
WO2005054181A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 抗癌剤の新規標的タンパク質および対応する新規抗癌剤（スプナール）
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US7070816B2 (en) 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7927821B2 (en) * 2004-04-12 2011-04-19 Takeda Pharmaceutical Company Limited Methods of screening for compounds which bind G protein-coupled receptors
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
ZA200704251B (en) * 2004-10-28 2008-11-26 Celgene Corp Methods and compositions using PDE4 modulators for treatment and management of central nervous injury
WO2006056770A1 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2006133926A1 (en) * 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
HUP0500730A2 (en) * 2005-07-29 2007-02-28 Richter Gedeon Vegyuszeti Gyar 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
EP1915157A4 (de) 2005-08-02 2010-09-01 Nicox Sa Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
EP1954685A4 (de) 2005-11-16 2009-11-11 Nitromed Inc Furoxanverbindungen, zusammensetzungen und anwendungsverfahren
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US8067414B2 (en) 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (de) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmazeutische kombinationen
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
CA2682393C (en) * 2007-04-11 2015-03-17 Kissei Pharmaceutical Co., Ltd. 5-membered heterocyclic derivative and use thereof for medical purposes
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20090062364A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched celecoxib
US8501778B2 (en) 2008-06-20 2013-08-06 Nhwa Pharma. Corporation Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
EP2177215A1 (de) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-Kristalle von Tramadol und NSARs
SG10201900514RA (en) 2008-10-22 2019-02-27 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US8785466B2 (en) * 2008-10-31 2014-07-22 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US8686017B2 (en) * 2008-10-31 2014-04-01 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050944A1 (en) 2009-10-28 2011-05-05 Ratiopharm Gmbh Formulations containing celecoxib
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
KR20130053404A (ko) 2010-03-30 2013-05-23 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
US9079899B2 (en) 2010-11-01 2015-07-14 The Ohio State University Anti-staphylococcal celecoxib derivatives
CN102746231A (zh) * 2011-04-20 2012-10-24 天津药物研究院 塞来昔布制备工艺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2013187965A1 (en) * 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
CN102746232A (zh) * 2012-07-03 2012-10-24 石药集团中诺药业（石家庄）有限公司 一种塞来昔布杂质的制备方法
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
JP6352302B2 (ja) 2012-12-28 2018-07-04 ダウ アグロサイエンシィズ エルエルシー 穀類における真菌防除のための相乗性殺真菌性混合物
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
WO2014138616A2 (en) * 2013-03-08 2014-09-12 Translational Drug Development, Llc Pyrazole compounds and methods of use thereof
EP2968297B1 (de) 2013-03-15 2018-09-26 Verseon Corporation Multisubstituierte aromatische verbindungen als serinproteaseinhibitoren
CA2902431A1 (en) 2013-03-15 2014-09-25 Kevin Michael Short Halogenopyrazoles as inhibitors of thrombin
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104974091B (zh) * 2014-04-10 2018-01-02 沈阳药科大学 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
EP3699181B1 (de) 2014-11-16 2023-03-01 Array Biopharma, Inc. Kristalline form von (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid-schwefelwasserstoff
CN113173838A (zh) 2014-12-30 2021-07-27 美国陶氏益农公司 具有杀真菌活性的吡啶酰胺化合物
AU2015374375B2 (en) 2014-12-30 2019-03-21 Dow Agrosciences Llc Picolinamides with fungicidal activity
CA2972403A1 (en) 2014-12-30 2016-07-07 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
CN107427000A (zh) 2014-12-30 2017-12-01 美国陶氏益农公司 具有杀真菌活性的吡啶酰胺化合物的用途
MX2017008444A (es) 2014-12-30 2017-10-02 Dow Agrosciences Llc Picolinamidas como fungicidas.
EP3247353A4 (de) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclische itk-inhibitoren zur behandlung von entzündungen und krebs
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PL3261639T3 (pl) 2015-02-27 2022-12-19 Verseon International Corporation Podstawione związki pirazolowe jako inhibitory proteazy serynowej
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
EP3302429A1 (de) 2015-05-28 2018-04-11 Dr. Reddy's Laboratories Ltd. Orale zusammensetzung von celecoxib zur schmerzbehandlung
CN104945388A (zh) * 2015-07-09 2015-09-30 南京大学 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用
KR20180102544A (ko) 2015-10-26 2018-09-17 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
EP3413889A1 (de) 2016-02-10 2018-12-19 Cocoon Biotech Inc. Zusammensetzungen mit seidenfibroin mit benzenesulfonamidhaltigen nichtsteroidalen entzündungshemmenden wirkstoffen und einem geliermittel und verwendungen davon
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
CN109496151A (zh) 2016-05-27 2019-03-19 雷迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
CN109641884B (zh) 2016-08-18 2024-01-02 维达克制药有限公司 哌嗪衍生物、其药物组合物及其使用方法
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3062074A1 (en) 2017-05-02 2018-11-08 Dow Agrosciences Llc Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2018360059B2 (en) 2017-11-03 2023-07-13 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020033955A1 (en) 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
CN111039982A (zh) * 2018-10-12 2020-04-21 南京大学 一类含新型磷脂胺骨架的吡唑磺胺衍生物的设计、合成
KR20210076072A (ko) 2018-10-15 2021-06-23 코르테바 애그리사이언스 엘엘씨 옥시피콜린아미드의 합성 방법
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
SG11202108927UA (en) 2019-05-02 2021-09-29 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (zh) 2019-10-14 2023-03-21 因赛特公司 作为fgfr抑制剂的双环杂环
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
WO2022149937A2 (ko) 2021-01-08 2022-07-14 서울대학교 산학협력단 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5387693A (en) * 1991-08-08 1995-02-07 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole intermediate compounds
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1994014777A1 (en) * 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides

Also Published As

Publication number Publication date
KR100263817B1 (ko) 2000-08-16
JP2000109466A (ja) 2000-04-18
DE69429836D1 (de) 2002-03-21
PL314695A1 (en) 1996-09-16
DE10075033I1 (de) 2001-01-18
NZ276885A (en) 1999-08-30
US5753688A (en) 1998-05-19
DE69422306T4 (de) 2000-09-07
KR100261669B1 (en) 2000-07-15
DE10075033I2 (de) 2001-08-02
DE69429836T2 (de) 2002-07-18
DE69422306D1 (de) 2000-01-27
ES2172959T3 (es) 2002-10-01
CZ150396A3 (en) 1996-12-11
HU223824B1 (hu) 2005-02-28
DE69430930T2 (de) 2003-02-20
PL180717B1 (pl) 2001-03-30
FR09C0007I1 (de) 2009-04-17
ES2180233T3 (es) 2003-02-01
AU690609B2 (en) 1998-04-30
HU9601455D0 (en) 1996-07-29
JPH09506350A (ja) 1997-06-24
AU1171495A (en) 1995-06-19
DK0923933T3 (da) 2002-10-21
DE69430930D1 (de) 2002-08-08
ATE212985T1 (de) 2002-02-15
PT923933E (pt) 2002-10-31
DE69432193D1 (de) 2003-04-03
HK1021935A1 (en) 2000-07-21
NO962184D0 (no) 1996-05-29
CN1280125A (zh) 2001-01-17
ES2193609T3 (es) 2003-11-01
CY2009003I2 (el) 2009-11-04
NO962184L (no) 1996-05-29
ATE187965T1 (de) 2000-01-15
LU91538I2 (fr) 2009-05-06
US5760068A (en) 1998-06-02
HUT74180A (en) 1996-11-28
CN1134418C (zh) 2004-01-14
FI115053B (fi) 2005-02-28
LU90698I2 (fr) 2001-02-13
DE69422306T2 (de) 2000-05-18
CY2009003I1 (el) 2009-11-04
RU2139281C1 (ru) 1999-10-10
NL300024I1 (nl) 2001-01-02
NZ536355A (en) 2006-08-31
ES2141916T3 (es) 2000-04-01
ATE233245T1 (de) 2003-03-15
CN1141630A (zh) 1997-01-29
CN1127484C (zh) 2003-11-12
EP0731795A1 (de) 1996-09-18
GR3032696T3 (en) 2000-06-30
CA2276945C (en) 2006-08-01
CN1495170A (zh) 2004-05-12
JP3025017B2 (ja) 2000-03-27
EP0731795B1 (de) 1999-12-22
CZ294630B6 (cs) 2005-02-16
JP2003238536A (ja) 2003-08-27
RO118291B1 (ro) 2003-04-30
CY2237B1 (en) 2003-07-04
JP3445762B2 (ja) 2003-09-08
KR100229343B1 (ko) 1999-11-01
FR09C0007I2 (de) 2010-12-31
NO306460B1 (no) 1999-11-08
FI962249A (fi) 1996-05-29
NL300024I2 (nl) 2001-04-02
DE69432193T2 (de) 2004-01-15
ATE219937T1 (de) 2002-07-15
CA2276946A1 (en) 1995-06-08
DK0731795T3 (da) 2000-05-15
CA2177576C (en) 1999-10-26
HK1013649A1 (en) 1999-09-03
CN1280126A (zh) 2001-01-17
WO1995015316A1 (en) 1995-06-08
PT731795E (pt) 2000-05-31
NZ336428A (en) 2005-02-25
PT924201E (pt) 2002-06-28
CA2277954A1 (en) 1995-06-08
CA2177576A1 (en) 1995-06-08
CA2276945A1 (en) 1995-06-08
CN1268614C (zh) 2006-08-09
FI962249A0 (fi) 1996-05-29
JP3921451B2 (ja) 2007-05-30
CN1061036C (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
DK0924201T3 (da) Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer
ME00768B (me) Derivati supstituisanih benzol sulfonamida kao pro-lekovi cox-2 inhibitora
DK0679157T3 (da) Nye 3,4-diarylthiophener og analoge deraf til anvendelse som antiinflammatoriske midler
ATE114151T1 (de) Benzocyclobutyl- oder indanyl-alkyl-amino-alkyl substituierte 3-benzazepin-2-ones, verwendbar in der behandlung von kardiovaskularen krankheiten.
DK0731794T3 (da) 1,4,5-Triphenyl-pyrazolforbindelser til behandling af inflammation og inflammationsbeslægtede lidelser
AU4284196A (en) Substituted biphenyl compounds for the treatment of inflammation
BR9607035A (pt) Isoxazois substituidos para o tratamento de inflamação
BR9408078A (pt) Composto composição herbicida e processo para controlar vegetação indesejável
NO308249B1 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
DK0696273T3 (da) Carbamoylhydroxylaminer og deres anvendelse i polymerkemi
EA199900710A1 (ru) Кристаллическая гидратированная натриевая соль (е)-4,6-дихлор-3-(2-оксо-1-фенилпирролидин-3-илиденметил)-1н-индол-2-карбоновой кислоты
NO960271D0 (no) Tiokarbamoylforbindelser anvendt som mikrobiocider